Skip to main content
Johanna Bendell, MD, Oncology, Nashville, TN

Johanna Chock Bendell MD


Physician

Join to View Full Profile
  • 250 25th Ave NSte 100Nashville, TN 37203

  • Phone+1 615-320-5090

Join Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 5 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Summary

  • Dr. Johanna Bendell, MD is an oncologist in Nashville, Tennessee. She is currently licensed to practice medicine in Tennessee and North Carolina.

Education & Training

  • Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer Institute
    Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003
  • Mass General Brigham/Brigham and Women's Hospital
    Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1998 - 2001
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2008 - 2023
  • NC State Medical License
    NC State Medical License 2020 - 2022

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
  • CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017
  • CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2014, 2016-2017

Publications & Presentations

PubMed

Press Mentions

  • XTANDI® plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
    XTANDI® plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate CancerOctober 19th, 2025
  • TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial
    TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 TrialOctober 14th, 2025
  • PADCEV™ plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
    PADCEV™ plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After SurgeryAugust 12th, 2025